Tiagabine for the Treatment of Cocaine Dependence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-10-31

Study Completion Date

2004-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess tiagabine for the treatment of cocaine dependence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1

NCT00129298

COMPLETED PHASE2

Ritanserin in Treatment of Cocaine Dependence - 1

NCT00000187

Cocaine-Related Disorders

COMPLETED PHASE2

Improving Learning-based Treatment of Cocaine Dependence With Medication

NCT01526538

COCAINE-RELATED DISORDERS

COMPLETED PHASE2

Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1

NCT00032929

Cocaine-Related Disorders

COMPLETED PHASE3

Assessment of Potential Interactions Between Cocaine and RPR 102681 - 1

NCT00067535

Cocaine-Related Disorders

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess the efficacy and safety of tiagabine in reducing cocaine use in subjects with cocaine dependence. It is hypothesized that tiagabine treatment, compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (BE). This is a double-blind, placebo-controlled, parallel-group design study, in which, after screening and a 2-week baseline assessment period, subjects will be equally randomly assigned to 1 of 2 treatment groups, tiagabine or matched placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cocaine-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tiagabine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Must be at least 18 years of age and be seeking treatment for cocaine dependence. Have the ability to understand, and having understood, provide written informed consent. If female, agree to use a method of birth control as indicated by the clinician. Please contact the participating site in your area for more information.